daniel-fung-shutterstock-com
Daniel Fung / Shutterstock.com
23 June 2015Asia-Pacific

SIPO rejects Gilead’s Sovaldi patent application

China’s State Intellectual Property Office (SIPO) has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
11 February 2015   A medical aid non-profit organisation has opposed a European patent held by pharmaceutical company Gilead that covers its anti-hepatitis C drug Sovaldi.
Americas
20 May 2015   Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.

More on this story

Big Pharma
11 February 2015   A medical aid non-profit organisation has opposed a European patent held by pharmaceutical company Gilead that covers its anti-hepatitis C drug Sovaldi.
Americas
20 May 2015   Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.

More on this story

Big Pharma
11 February 2015   A medical aid non-profit organisation has opposed a European patent held by pharmaceutical company Gilead that covers its anti-hepatitis C drug Sovaldi.
Americas
20 May 2015   Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.